Seizing the Precision Care Moment in MDS: Collaborative Strategies for Accurate Diagnoses and Risk-Adapted Treatment

•Download as PPT, PDF•

0 likes•12 views

PVI, PeerView Institute for Medical Education

Co-Chairs, Rami Komrokji, MD, and Cecilia CS Yeung, MD, discuss myelodysplastic syndromes in this CME/MOC/CC activity titled “Seizing the Precision Care Moment in MDS: Collaborative Strategies for Accurate Diagnoses and Risk-Adapted Treatment.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/CC information, and to apply for credit, please visit us at https://bit.ly/3DimKor. CME/MOC/CC credit will be available until April 12, 2024.

Health & Medicine

Seizing the Precision Care Moment in MDS: Collaborative Strategies for Accurate Diagnoses and Risk-Adapted Treatment

Co-Chairs Riad Salem, MD, MBA, and Mark Yarchoan, MD, discuss liver cancer in this CME/MOC activity titled “Establishing the Collaborative Benchmark for HCC Care: Critical Discussions Between Interventional Radiologists and Oncologists to Maximize Therapeutic Benefit.” For the full presentation, downloadable Practice Aids, and complete CME/MOC information, and to apply for credit, please visit us at https://bit.ly/3IOQvQ6. CME/MOC credit will be available until June 14, 2025.

Bridging the Gap to Improved Outcomes in Non-Cystic Fibrosis Bronchiectasis: ...

PVI, PeerView Institute for Medical Education

Co-Chairs, Brett Elicker, MD, and David E. Griffith, MD, ATSF, ACCP, OFRSM, prepared useful Practice Aids pertaining to non-cystic fibrosis bronchiectasis for this CME/MOC activity titled “Bridging the Gap to Improved Outcomes in Non-Cystic Fibrosis Bronchiectasis: Ensuring Prompt Diagnosis Through Accurate Interpretation of CT Imaging.” For the full presentation, downloadable Practice Aids, and complete CME/MOC information, and to apply for credit, please visit us at https://bit.ly/48WUULu. CME/MOC credit will be available until June 4, 2025.

Bridging the Gap to Improved Outcomes in Non-Cystic Fibrosis Bronchiectasis: ...

PVI, PeerView Institute for Medical Education

Co-Chairs, Brett Elicker, MD, and David E. Griffith, MD, ATSF, ACCP, OFRSM, discuss non-cystic fibrosis bronchiectasis in this CME/MOC activity titled “Bridging the Gap to Improved Outcomes in Non-Cystic Fibrosis Bronchiectasis: Ensuring Prompt Diagnosis Through Accurate Interpretation of CT Imaging.” For the full presentation, downloadable Practice Aids, and complete CME/MOC information, and to apply for credit, please visit us at https://bit.ly/48WUULu. CME/MOC credit will be available until June 4, 2025.

Applying Advances in PET Imaging to Facilitate the Early Diagnosis of Alzheim...

PVI, PeerView Institute for Medical Education

Co-Chairs, Jonathan E. McConathy, MD, PhD, and Gil Rabinovici, MD, discuss Alzheimer's disease in this CME/AAPA activity titled “Applying Advances in PET Imaging to Facilitate the Early Diagnosis of Alzheimer’s Disease: Preparing Nuclear Medicine and Radiology Specialists for New Diagnostic Workflows.” For the full presentation, downloadable Practice Aids, and complete CME/AAPA information, and to apply for credit, please visit us at https://bit.ly/45RFl6g. CME/AAPA credit will be available until June 15, 2025.

A Pharmacist’s Take on Navigating the Expanding Therapeutic Landscape for End...

PVI, PeerView Institute for Medical Education

Co-Chairs Sarah Hayward, PharmD, BCOP, and Ambar Khan, PharmD, BCOP, discuss endometrial and cervical cancers in this CME/CPE/IPCE activity titled “A Pharmacist’s Take on Navigating the Expanding Therapeutic Landscape for Endometrial and Cervical Cancers: Insights on Coordinating and Delivering Effective Modern Care.” For the full presentation, downloadable Practice Aids, and complete CME/CPE/IPCE information, and to apply for credit, please visit us at https://bit.ly/3wGBPQp. CME/CPE/IPCE credit will be available until May 27, 2025.

“Four-Ward” Progress in NDMM: New Developments With CD38 Antibody Quadruplets

PVI, PeerView Institute for Medical Education

Transforming Care and Outcomes With Immunotherapy in Stage I-III Resectable N...

PVI, PeerView Institute for Medical Education

Co-Chairs, Jessica Donington, MD, and Jonathan D. Spicer, MD, PhD, FRCSC, prepared useful Practice Aids pertaining to lung cancer for this CME/MOC/AAPA activity titled “Transforming Care and Outcomes With Immunotherapy in Stage I-III Resectable NSCLC: A Case Exploration of New Standards and Emerging Approaches.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at https://bit.ly/3TxdcP5. CME/MOC/AAPA credit will be available until June 7, 2025.

Transforming Care and Outcomes With Immunotherapy in Stage I-III Resectable N...

PVI, PeerView Institute for Medical Education

Co-Chairs, Jessica Donington, MD, and Jonathan D. Spicer, MD, PhD, FRCSC, discuss lung cancer in this CME/MOC/AAPA activity titled “Transforming Care and Outcomes With Immunotherapy in Stage I-III Resectable NSCLC: A Case Exploration of New Standards and Emerging Approaches.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at https://bit.ly/3TxdcP5. CME/MOC/AAPA credit will be available until June 7, 2025.

Chair and Presenters, Neal D. Shore, MD, FACS, Ashish M. Kamat, MD, MBBS, and Joshua J. Meeks, MD, PhD, prepared useful Practice Aids pertaining to bladder cancer for this CME/MOC/NCPD/AAPA/IPCE activity titled “Harnessing Innovation in Bladder Cancer Care: Strategies for Effectively Implementing Modern Therapeutic Advances Across the Disease Continuum.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at https://bit.ly/3PH0RVQ. CME/MOC/NCPD/AAPA/IPCE credit will be available until June 2, 2025.

Harnessing Innovation in Bladder Cancer Care: Strategies for Effectively Impl...

PVI, PeerView Institute for Medical Education

Chair and Presenters, Neal D. Shore, MD, FACS, Ashish M. Kamat, MD, MBBS, and Joshua J. Meeks, MD, PhD, discuss bladder cancer in this CME/MOC/NCPD/AAPA/IPCE activity titled “Harnessing Innovation in Bladder Cancer Care: Strategies for Effectively Implementing Modern Therapeutic Advances Across the Disease Continuum.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at https://bit.ly/3PH0RVQ. CME/MOC/NCPD/AAPA/IPCE credit will be available until June 2, 2025.

Striking Back at ALL: Achieving Lasting Benefits with Bispecific Antibodies &...

PVI, PeerView Institute for Medical Education

Chair, Nicholas J. Short, MD, discusses acute lymphoblastic leukemia in this CME/NCPD/CPE/AAPA/IPCE activity titled “Striking Back at ALL: Achieving Lasting Benefits with Bispecific Antibodies & MRD-Guided Strategies Across Disease Settings.” For the full presentation, downloadable Practice Aids, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at https://bit.ly/42QsTDT. CME/NCPD/CPE/AAPA/IPCE credit will be available until May 22, 2025.

Specialty Training for the New Era in Alzheimer’s Disease: Building Skills fo...

PVI, PeerView Institute for Medical Education

Chair, Sharon Cohen, MD, FRCPC, prepared useful Practice Aids pertaining to Alzheimer’s disease for this CME/MOC/AAPA activity titled “Specialty Training for the New Era in Alzheimer’s Disease: Building Skills for Making an Early Diagnosis and Implementing Disease-Modifying Treatment.” For the full presentation, downloadable Practice Aids, monograph, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at https://bit.ly/472bp8g. CME/MOC/AAPA credit will be available until May 20, 2025.

Specialty Training for the New Era in Alzheimer’s Disease: Building Skills fo...

PVI, PeerView Institute for Medical Education

Chair, Sharon Cohen, MD, FRCPC, discusses Alzheimer’s disease in this CME/MOC/AAPA activity titled “Specialty Training for the New Era in Alzheimer’s Disease: Building Skills for Making an Early Diagnosis and Implementing Disease-Modifying Treatment.” For the full presentation, downloadable Practice Aids, monograph, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at https://bit.ly/472bp8g. CME/MOC/AAPA credit will be available until May 20, 2025.

Ten Steps for Highly Successful Myeloma Care: Guidance on the Road to Remissi...

PVI, PeerView Institute for Medical Education

Chair and Presenter, Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO, Donna D. Catamero, ANP-BC, OCN, CCRC, and Charise Gleason, MSN, NP-C, AOCNP, discuss multiple myeloma in this CME/MOC/NCPD/ILNA/IPCE activity titled “Ten Steps for Highly Successful Myeloma Care: Guidance on the Road to Remission With Antibodies, BCMA Immunotherapy, and Other Innovations.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/NCPD/ILNA/IPCE information, and to apply for credit, please visit us at https://bit.ly/47mtUnM. CME/MOC/NCPD/ILNA/IPCE credit will be available until May 25, 2025.

Making Patient-Centric Immunotherapy a Reality in Lung Cancer: Best Practices...

PVI, PeerView Institute for Medical Education

Co-Chairs and Presenter Marianne Davies, DNP, ACNP, AOCNP, FAAN, Beth Sandy, MSN, CRNP, FAPO, and Matthew A. Gubens, MD, MS, FASCO, prepared useful Practice Aids pertaining to NSCLC for this CME/MOC/NCPD/ILNA/IPCE activity titled “Making Patient-Centric Immunotherapy a Reality in Lung Cancer: Best Practices for Patient Education, irAE Management, and Survivorship Care.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/NCPD/ILNA/IPCE information, and to apply for credit, please visit us at https://bit.ly/3RDokbZ. CME/MOC/NCPD/ILNA/IPCE credit will be available until May 24, 2025.

Making Patient-Centric Immunotherapy a Reality in Lung Cancer: Best Practices...

PVI, PeerView Institute for Medical Education

Co-Chairs and Presenter Marianne Davies, DNP, ACNP, AOCNP, FAAN, Beth Sandy, MSN, CRNP, FAPO, and Matthew A. Gubens, MD, MS, FASCO, discuss NSCLC in this CME/MOC/NCPD/ILNA/IPCE activity titled “Making Patient-Centric Immunotherapy a Reality in Lung Cancer: Best Practices for Patient Education, irAE Management, and Survivorship Care.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/NCPD/ILNA/IPCE information, and to apply for credit, please visit us at https://bit.ly/3RDokbZ. CME/MOC/NCPD/ILNA/IPCE credit will be available until May 24, 2025.

Modern Team-Based Therapeutic Management for Bladder Cancer Care: Expert Stra...

PVI, PeerView Institute for Medical Education

Co-Chairs, Sia Daneshmand, MD, and Matthew D. Galsky, MD, discuss bladder cancer in this CME/MOC/NCPD/AAPA/IPCE activity titled “Modern Team-Based Therapeutic Management for Bladder Cancer Care: Expert Strategies for Integrating the Latest Evidence and Treatment Advances.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at https://bit.ly/3OOeYbO. CME/MOC/NCPD/AAPA/IPCE credit will be available until May 13, 2025.

Nurses at the Forefront of Maximizing the Potential of TROP2-Targeted Therapy...

PVI, PeerView Institute for Medical Education

Chair Jamie Carroll, APRN, CNP, MSN, discusses breast cancer in this NCPD/ILNA/AAPA activity titled “Nurses at the Forefront of Maximizing the Potential of TROP2-Targeted Therapy in TNBC and HR+, HER2- Breast Cancer: Best Practices for Adverse Event Management and Patient Education.” For the full presentation, downloadable Practice Aids, and complete NCPD/ILNA/AAPA information, and to apply for credit, please visit us at https://bit.ly/3SdnvWt. NCPD/ILNA/AAPA credit will be available until May 8, 2025.

BTK Inhibition Transforming the Landscape of Chronic Spontaneous Urticaria Tr...

PVI, PeerView Institute for Medical Education

Adapting Managed Care Strategies in the Era of Precision Medicine for Hypertr...

PVI, PeerView Institute for Medical Education

Co-Chairs Milind Desai, MD, MBA, FACC, FAHA, FESC, and Andrew Willeford, PharmD, PhD, BCCP, prepared useful Practice Aids pertaining to hypertrophic cardiomyopathy for this CME/MOC/CPE/AAPA/IPCE activity titled “Adapting Managed Care Strategies in the Era of Precision Medicine for Hypertrophic Cardiomyopathy.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/CPE/AAPA/IPCE information, and to apply for credit, please visit us at https://bit.ly/4bb7eKc. CME/MOC/CPE/AAPA/IPCE credit will be available until May 16, 2025.

Adapting Managed Care Strategies in the Era of Precision Medicine for Hypertr...

PVI, PeerView Institute for Medical Education

Co-Chairs Milind Desai, MD, MBA, FACC, FAHA, FESC, and Andrew Willeford, PharmD, PhD, BCCP, discuss hypertrophic cardiomyopathy in this CME/MOC/CPE/AAPA/IPCE activity titled “Adapting Managed Care Strategies in the Era of Precision Medicine for Hypertrophic Cardiomyopathy.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/CPE/AAPA/IPCE information, and to apply for credit, please visit us at https://bit.ly/4bb7eKc. CME/MOC/CPE/AAPA/IPCE credit will be available until May 16, 2025.

Exploring the Evidence: Improving Cardiovascular Outcomes and the Role of Wei...

PVI, PeerView Institute for Medical Education

Interdisciplinary Approaches to Management of Immune-Mediated Inflammatory Di...

PVI, PeerView Institute for Medical Education

Co-Chairs and Planners Saakshi Khattri, MBBS, MD, FAAD, FACR, Marla Dubinsky, MD, Emma Guttman-Yassky, MD, PhD, and Alexis Ogdie, MD, MSCE, discuss immune-mediated inflammatory diseases in this CME/AAPA activity titled “Interdisciplinary Approaches to Management of Immune-Mediated Inflammatory Diseases: Addressing Shared Pathophysiology With JAK Inhibitors.” For the full presentation, downloadable Practice Aids, and complete CME/AAPA information, and to apply for credit, please visit us at https://bit.ly/3JhsIZ7. CME/AAPA credit will be available until April 24, 2025.

Treatment Advances and Individualized Therapeutic Strategies in Prostate Canc...

PVI, PeerView Institute for Medical Education

Co-Chairs Alicia K. Morgans, MD, MPH, and Neal D. Shore, MD, FACS, discuss prostate cancer in this CME/MOC/NCPD/CPE/AAPA/IPCE activity titled “Treatment Advances and Individualized Therapeutic Strategies in Prostate Cancer: Expert Insights on Key Evidence, Practical Tips for Personalized Therapy, and Clinical Integration Approaches.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at https://bit.ly/3SQrJ6G. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until April 24, 2025.

Charting a New Path to Better Outcomes With TROP2-Targeting ADCs in Lung Canc...

PVI, PeerView Institute for Medical Education

Co-Chairs Prof. Nicolas Girard, MD, PhD, and Aaron Lisberg, MD, discuss NSCLC in this CME/MOC/NCPD/AAPA/IPCE activity titled “Charting a New Path to Better Outcomes With TROP2-Targeting ADCs in Lung Cancer: Unveiling Potential, Shaping Tomorrow.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at https://bit.ly/3RmX3dU. CME/MOC/NCPD/AAPA/IPCE credit will be available until April 24, 2025.

Biologics in CRSwNP: Putting a Paradigm Shift Into Practice

PVI, PeerView Institute for Medical Education

Co-Chairs, Joseph K. Han, MD, and Seth J. Isaacs, MD, prepared useful Practice Aids pertaining to chronic rhinosinusitis with nasal polyps for this CME/MOC/CC/AAPA/IPCE activity titled “Biologics in CRSwNP: Putting a Paradigm Shift Into Practice.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/CC/AAPA/IPCE information, and to apply for credit, please visit us at https://bit.ly/3Tq6n1G. CME/MOC/CC/AAPA/IPCE credit will be available until May 6, 2025.

Biologics in CRSwNP: Putting a Paradigm Shift Into Practice

PVI, PeerView Institute for Medical Education

Co-Chairs, Joseph K. Han, MD, and Seth J. Isaacs, MD, discuss chronic rhinosinusitis with nasal polyps in this CME/MOC/CC/AAPA/IPCE activity titled “Biologics in CRSwNP: Putting a Paradigm Shift Into Practice.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/CC/AAPA/IPCE information, and to apply for credit, please visit us at https://bit.ly/3Tq6n1G. CME/MOC/CC/AAPA/IPCE credit will be available until May 6, 2025.

Couples presenting to the infertility clinic- Do they really have infertility...

Sujoy Dasgupta

ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx

Swetaba Besh

Recently uploaded

Couples presenting to the infertility clinic- Do they really have infertility...

Sujoy Dasgupta

ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx

Swetaba Besh

Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock

rebeccabio

Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock Telegram: bmksupplier signal: +85264872720 threema: TUD4A6YC You can contact me on Telegram or Threema Communicate promptly and reply Free of customs clearance, Double Clearance 100% pass delivery to USA, Canada, Spain, Germany, Netherland, Poland, Italy, Sweden, UK, Czech Republic, Australia, Mexico, Russia, Ukraine, Kazakhstan.Door to door service Hot Selling Organic intermediates

Report Back from SGO 2024: What’s the Latest in Cervical Cancer?

bkling

Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.

BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf

DR SETH JOTHAM

The prostate is an exocrine gland of the male mammalian reproductive system It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ). It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes It’s work is regulated by androgens which are responsible for male sex characteristics Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS

Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf

Dr Jeenal Mistry

Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol that is rapidly distributed in the body and brain. Ethanol alters many neurochemical systems and has rewarding and addictive properties. It is the oldest recreational drug and likely contributes to more morbidity, mortality, and public health costs than all illicit drugs combined. The 5th edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) integrates alcohol abuse and alcohol dependence into a single disorder called alcohol use disorder (AUD), with mild, moderate, and severe subclassifications (American Psychiatric Association, 2013). In the DSM-5, all types of substance abuse and dependence have been combined into a single substance use disorder (SUD) on a continuum from mild to severe. A diagnosis of AUD requires that at least two of the 11 DSM-5 behaviors be present within a 12-month period (mild AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria). The four main behavioral effects of AUD are impaired control over drinking, negative social consequences, risky use, and altered physiological effects (tolerance, withdrawal). This chapter presents an overview of the prevalence and harmful consequences of AUD in the U.S., the systemic nature of the disease, neurocircuitry and stages of AUD, comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and pharmacotherapies for AUD.

BRACHYTHERAPY OVERVIEW AND APPLICATORS

Krishan Murari

Are There Any Natural Remedies To Treat Syphilis.pdf

Little Cross Family Clinic

Physiology of Chemical Sensation of smell.pdf

MedicoseAcademics

Title: Sense of Smell Presenter: Dr. Faiza, Assistant Professor of Physiology Qualifications: MBBS (Best Graduate, AIMC Lahore) FCPS Physiology ICMT, CHPE, DHPE (STMU) MPH (GC University, Faisalabad) MBA (Virtual University of Pakistan) Learning Objectives: Describe the primary categories of smells and the concept of odor blindness. Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction. Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain. Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential. Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes. Key Topics: Olfactory Genes: 3% of the human genome accounts for olfactory genes. 400 genes for odorant receptors. Olfactory Membrane: Located in the superior part of the nasal cavity. Medially: Folds downward along the superior septum. Laterally: Folds over the superior turbinate and upper surface of the middle turbinate. Total surface area: 5-10 square centimeters. Olfactory Mucosa: Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell. Sustentacular Cells: Produce mucus and maintain ionic and molecular environment. Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months. Bowman’s Gland: Secretes mucus. Stimulation of Olfactory Cells: Odorant dissolves in mucus and attaches to receptors on olfactory cilia. Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve. Quality of a Good Odorant: Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble. Facilitated by odorant-binding proteins in mucus. Membrane Potential and Action Potential: Resting membrane potential: -55mV. Action potential frequency in the olfactory nerve increases with odorant strength. Adaptation Towards the Sense of Smell: Rapid adaptation within the first second, with further slow adaptation. Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system. Primary Sensations of Smell: Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid. Odor Detection Threshold: Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm). Some toxic substances are odorless at lethal concentrations. Characteristics of Smell: Odor blindness for single substances due to lack of appropriate receptor protein. Behavioral and emotional influences of smell. Transmission of Olfactory Signals: From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition. Primitive, less old, and new olfactory systems with different path

KDIGO 2024 guidelines for diabetologists

د.محمود نجيب

Ocular injury ppt Upendra pal optometrist upums saifai etawah

pal078100

24 Upakrama.pptx class ppt useful in all

DrSathishMS1

New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...

i3 Health

i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource. This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and Associate Division Director for Ambulatory Operations The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma. STATEMENT OF NEED Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL. Target Audience Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL). Learning Objectives 1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL 2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults 3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection

The Normal Electrocardiogram - Part I of II

MedicoseAcademics

These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram. Learning objectives: 1. Define an electrocardiogram (ECG) and electrocardiography 2. Describe how dipoles generated by the heart produce the waveforms of the ECG 3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II) 4. Differentiate between intervals and segments 5. Enlist some common indications for obtaining an ECG Study Resources: 1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition 2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition 3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition 4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/ 5. ECG in Medical Practice by ABM Abdullah, 4th edition 6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics

Superficial & Deep Fascia of the NECK.pptx

Dr. Rabia Inam Gandapore

TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...

kevinkariuki227

The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...

Catherine Liao

The hemodynamic and autonomic determinants of elevated blood pressure in obes...

Catherine Liao

Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...

Savita Shen $i11

HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...

GL Anaacs

Contact us if you are interested: Email / Skype : kefaya1771@gmail.com Threema: PXHY5PDH New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH ! Contact me on Threema or skype to start big business!! Hot-sale products: NEW HOT EUTYLONE WHITE CRYSTAL!! 5cl-adba precursor (semi finished ) 5cl-adba raw materials ADBB precursor (semi finished ) ADBB raw materials APVP powder 5fadb/4f-adb Jwh018 / Jwh210 Eutylone crystal Protonitazene (hydrochloride) CAS: 119276-01-6 Flubrotizolam CAS: 57801-95-3 Metonitazene CAS: 14680-51-4 Payment terms: Western Union,MoneyGram,Bitcoin or USDT. Deliver Time: Usually 7-15days Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet. Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details. We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.

Recently uploaded (20)

Couples presenting to the infertility clinic- Do they really have infertility...

ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx

Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock

Report Back from SGO 2024: What’s the Latest in Cervical Cancer?

BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf

Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf

BRACHYTHERAPY OVERVIEW AND APPLICATORS

Are There Any Natural Remedies To Treat Syphilis.pdf

Physiology of Chemical Sensation of smell.pdf

KDIGO 2024 guidelines for diabetologists

Ocular injury ppt Upendra pal optometrist upums saifai etawah

24 Upakrama.pptx class ppt useful in all

New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...

The Normal Electrocardiogram - Part I of II

Superficial & Deep Fascia of the NECK.pptx

TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...

The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...

The hemodynamic and autonomic determinants of elevated blood pressure in obes...

Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...

HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...

Seizing the Precision Care Moment in MDS: Collaborative Strategies for Accurate Diagnoses and Risk-Adapted Treatment

Recommended

Recommended

More Related Content

More from PVI, PeerView Institute for Medical Education

More from PVI, PeerView Institute for Medical Education (20)

Recently uploaded

Recently uploaded (20)